Topline results: Donanemab superior to aducanumab in early symptomatic Alzheimer's disease

BOSTON — More patients with early symptomatic Alzheimer’s disease reached amyloid clearance and plaque reductions at 6 months with donanemab vs. aducanumab, according to a presentation at the American Academic of Neurology annual meeting. Stephen P. Salloway, MD, MS, the Martin M. Zucker Professor of Psychiatry and Human Behavior and professor of neurology at Brown University

Related Keywords

United States ,Boston ,Massachusetts ,American ,Heather Biele ,Stephenp Salloway ,Byjoan Marie Stiglich ,Martinm Zucker , ,American Academy Of Neurology ,Brown University Warren Alpert Medical School ,Genentech ,Joan Marie Stiglich ,American Academy ,Scientific Advisory Board ,American Academic ,Human Behavior ,